Diagnostic value of sentinel lymph node scintigraphy and 2‐[18F]‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography/computed tomography in the detection of metastatic lymph nodes in patients with early‐stage cervical cancer

Abstract

Cervical cancer is staged clinically using the International Federation of Gynaecology and Obstetrics staging system. Although lymph node status does not form part of the staging, it has important prognostic and potential therapeutic implications. The aim of the study was to evaluate the role of sentinel lymph node (SLN) scintigraphy and 2‑[18F]‑fluoro‑2‑deoxy‑D‑glucose positron emission tomography/computed tomography (18F‑FDG PET/CT) in detecting lymph node metastases in patients with early‑stage cervical cancer. Thirty‑six patients with early‑stage cervical cancer underwent SLN detection during primary operation. Of the 36 patients, 28 patients underwent 18F‑FDG PET/CT before surgery. The 18F‑FDG PET/CT images were analyzed with the histopathological findings as the reference standard. The diagnostic performance of 18F‑FDG PET/CT in the detection of nodal disease was reported in terms of accuracy value. The SLN detection rate was the highest (91.7%) using the combined method (lymphoscintigraphy, intraoperative gamma probe, and blue dye). Seven of the thirty‑six patients had lymph node involvement (19.4%), of which five had preoperative 18F‑FDG PET/CT imaging. On overall patient‑based analysis, the sensitivity, specificity, positive predictive value, negative predictive value (NPV), and accuracy of 18F‑FDG PET/CT were 40.0%, 78.3%, 28.6%, 85.7%, and 71.4%, respectively. The combination of radiolabeled nanocolloid with blue dye is safe and reliable and allows successful detection of SLNs in patients with early‑stage cervical cancer in a population with high prevalence of human immunodeficiency virus. The specificity and NPV of 18F‑FDG PET/CT are high and can be used in conjunction with SLN biopsy.